OASIS-6: should patients with acute ST-segment elevation myocardial infarction be treated with fondaparinux?
Lori-Ann Linkins and Jeffrey I Weitz*
Correspondence *Henderson Research Centre, 711 Concession Street, Hamilton, ON L8V 1C3, Canada
Email jweitz@thrombosis.hhscr.org
This article has no abstract so we have provided the first paragraph of the full text.
The OASIS-6 study compared fondaparinux, a synthetic pentasaccharide that catalyzes factor Xa inhibition by antithrombin, with usual care in patients with STEMI. Overall, fondaparinux was superior to usual care at reducing the 30-day death or reinfarction risk.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
